SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-20-009262
Filing Date
2020-02-13
Accepted
2020-02-13 16:44:32
Documents
2
Period of Report
2020-02-12

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1555
2 POA DOCUMENT poa.txt EX-24.3_894678 2990
  Complete submission text file 0001209191-20-009262.txt   5934
Mailing Address 22 BOSTON WHARF RD 9TH FLOOR BOSTON MA 02210
Business Address 22 BOSTON WHARF RD 9TH FLOOR BOSTON MA 02210 617-207-0202
AKCEA THERAPEUTICS, INC. (Issuer) CIK: 0001662524 (see all company filings)

IRS No.: 472608175 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O AVALANCHE BIOTECHNOLOGIES, INC. 1035 O'BRIEN DRIVE MENLO PARK CA 94025
Business Address
Salzman Amber (Reporting) CIK: 0001674536 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38137 | Film No.: 20611464